Reviewing Phio Pharmaceuticals Corp. (PHIO)’s and Esperion Therapeutics Inc. (NASDAQ:ESPR)’s results

As Biotechnology businesses, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) and Esperion Therapeutics Inc. (NASDAQ:ESPR), are affected by compare. This especially applies to their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Phio Pharmaceuticals Corp. N/A 49.86 7.63M -2.54 0.00
Esperion Therapeutics Inc. N/A 0.00 201.81M -6.75 0.00

Table 1 highlights Phio Pharmaceuticals Corp. and Esperion Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Phio Pharmaceuticals Corp. 0.00% -411.5% -179.4%
Esperion Therapeutics Inc. 0.00% -91.3% -77.2%

Volatility & Risk

Phio Pharmaceuticals Corp. is 99.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 1.99. Esperion Therapeutics Inc.’s 115.00% more volatile than Standard and Poor’s 500 volatility due to the stock’s 2.15 beta.


Phio Pharmaceuticals Corp.’s Current Ratio is 1.8 while its Quick Ratio is 1.8. On the competitive side is, Esperion Therapeutics Inc. which has a 4 Current Ratio and a 4 Quick Ratio. Esperion Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Phio Pharmaceuticals Corp.

Analyst Ratings

The table delivered features the ratings and recommendations for Phio Pharmaceuticals Corp. and Esperion Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Phio Pharmaceuticals Corp. 0 0 0 0.00
Esperion Therapeutics Inc. 1 3 4 2.50

Esperion Therapeutics Inc. on the other hand boasts of a $67.75 average target price and a 35.85% potential upside.

Institutional and Insider Ownership

Institutional investors held 16.1% of Phio Pharmaceuticals Corp. shares and 0% of Esperion Therapeutics Inc. shares. Insiders held roughly 3% of Phio Pharmaceuticals Corp.’s shares. On the other hand, insiders held about 2.2% of Esperion Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Phio Pharmaceuticals Corp. -0.73% 3.84% 22.3% -75.86% -86.46% 14.88%
Esperion Therapeutics Inc. -1.37% -0.52% -11.78% -7.08% -39.96% 0.46%

For the past year Phio Pharmaceuticals Corp. has stronger performance than Esperion Therapeutics Inc.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.